Gilead reinforces oncology department from Novartis
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Pharmaceuticals, Biotechnology and Life Sciences
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.
France’s Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.
Shire will now be able to use its Adynovate for treating heamophilia A in children younger than 12 years of age, as the the U.S. Food and Drug Administration (FDA) has approved it for that age group. The FDA has also…
A drug distributor owned by Cardinal Health Inc has agreed to pay $10 million to resolve claims that it failed to alert the U.S. Drug Enforcement Administration to suspicious orders of addictive painkillers by New York-area pharmacies.
Israeil’s largest drugmaker Teva Pharmaceuticals Industries has settled with the United States government over international bribery of government officials in…
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…